Connection
Christopher Wardell to Biomarkers, Pharmacological
This is a "connection" page, showing publications Christopher Wardell has written about Biomarkers, Pharmacological.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.050 |
|
|
|
-
Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gonzalez D, Walker BA, Hockley SL, Wardell CP, Gregory WM, Child JA, Jackson GH, Davies FE, Morgan GJ. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer. 2011 10; 50(10):765-74.
Score: 0.026
-
Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE, Morgan GJ. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma. 2010 Nov; 51(11):2126-9.
Score: 0.024